

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(1) Sodium</b>					359								359	353	98%								0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		129	2,0	1,6	359	CVP	129	0,26	4%	123	135	359	355	99%								0	
(2) Indirect ISE		129	1,9	1,5	308							308											
(3) Direct ISE		130	2,5	1,9	50							50											
Other					1							1											
						Ix 99																	
<b>Sample B</b>		117	1,8	1,5	359	CVP	117	0,23	4%	112	122	359	355	99%								0	
(2) Indirect ISE		116	1,7	1,5	308							308											
(3) Direct ISE		117	2,5	2,1	50							50											
Other					1							1											
						Ix 99																	
<b>(2) Potassium</b>					359								359	356	99%								0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		3,92	0,08	2,2	359	CVP	3,92	0,011	6%	3,68	4,16	359	356	99%								0	
(2) Indirect ISE		3,92	0,08	2,1	309							309											
(3) Direct ISE		3,92	0,10	2,5	49							49											
Other					1							1											
						Ix 99																	
<b>Sample B</b>		3,33	0,07	2,3	359	CVP	3,33	0,099	6%	3,13	3,53	359	356	99%								0	
(2) Indirect ISE		3,33	0,07	2,2	309							309											
(3) Direct ISE		3,33	0,09	2,9	49							49											
Other					1							1											
						Ix 99																	
<b>(3) Chloride</b>					359								359	349	97%								0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		118	2,6	2,2	359	CVP	118	0,33	7%	109	127	359	354	99%								0	
(3) Indirect ISE		118	2,5	2,1	311							311											
(4) Direct ISE		117	3,1	2,7	46							46											
Other					2							2											
						Ix 2, Ix 99																	
<b>Sample B</b>		94,3	2,5	2,7	359	CVP	94,3	0,33	7%	87,6	101	359	351	98%								0	
(3) Indirect ISE		94,3	2,5	2,7	311							311											
(4) Direct ISE		94,0	2,6	2,8	46							46											
Other					2							2											
						Ix 2, Ix 99																	
<b>(4) Calcium</b>					332								332	320	96%								0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		2,46	0,05	2,1	332	CVP	2,46	0,071	7%	2,28	2,64	332	327	98%								0	
(2) Phot. with o-cresolftalexon		2,46	0,07	3,0	36							36											
(3) Photom. with arsenazo III		2,46	0,05	2,1	192							192											

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(4) Calcium</b>					332							332	320	96%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		2,46	0,05	2,1	332	CVP	2,46	0,071	7%	2,28	2,64	332	327	98%									0
(4) Photomet. with NM-BAPTA		2,46	0,04	1,9	94							94											
(6) ISE		2,49	0,01	0,59	9							9											
Other					1							1											
						1x 99																	
<b>Sample B</b>		1,83	0,04	2,4	332	CVP	1,83	0,060	7%	1,7	1,96	332	323	97%									0
(2) Phot. with o-cresolftalexon		1,80	0,05	2,8	36							36											
(3) Photom. with arsenazo III		1,84	0,04	2,4	192							192											
(4) Photomet. with NM-BAPTA		1,82	0,03	1,9	94							94											
(6) ISE		1,84	0,04	2,4	9							9											
Other					1							1											
						1x 99																	
<b>(5) Inorganic phosphate</b>					318							318	314	99%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		1,91	0,05	2,9	318	CVP	1,91	0,076	10%	1,71	2,11	318	315	99%									0
(1) UV-molybdate method		1,91	0,05	2,9	306							306											
(2) Reduction photometry		1,96	0,09	4,9	8							8											
Other					4							4											
						4x 3																	
<b>Sample B</b>		1,51	0,04	2,8	318	CVP	1,51	0,057	10%	1,35	1,67	318	314	99%									0
(1) UV-molybdate method		1,51	0,04	2,7	306							306											
(2) Reduction photometry		1,53	0,06	4,4	8							8											
Other					4							4											
						4x 3																	
<b>(6) Iron</b>					308							308	306	99%									0
Samples and groups	[µmol/L]																						
<b>Sample A</b>		37,4	1,0	2,7	308	CVP	37,4	0,14	15%	31,7	43,1	308	308	100%									0
(2) Method with ferrozine/ferene		37,5	1,0	2,7	239							239											
(4) Method with TPTZ		36,8	0,86	2,3	68							68											
Other					1							1											
						1x 99																	
<b>Sample B</b>		15,8	0,56	3,6	308	CVP	15,8	0,078	15%	13,4	18,2	308	306	99%									0
(2) Method with ferrozine/ferene		15,8	0,58	3,6	239							239											
(4) Method with TPTZ		15,7	0,48	3,1	68							68											
Other					1							1											
						1x 99																	
<b>(7) Magnesium</b>					305							305	300	98%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		1,48	0,04	3,1	305	CVP	1,48	0,065	11%	1,31	1,65	305	302	99%									0
(2) Photometry		1,48	0,04	3,1	253							253											
(4) UV enzyme method		1,48	0,04	3,2	50							50											
Other					2							2											
						1x 0, 1x 99																	
<b>Sample B</b>		1,19	0,03	3,3	305	CVP	1,19	0,054	11%	1,05	1,33	305	303	99%									0
(2) Photometry		1,19	0,03	3,3	253							253											
(4) UV enzyme method		1,18	0,03	2,9	50							50											

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability						Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(7) Magnesium</b>					305							305	300	98%								0		
Samples and groups																								
<b>Sample B</b>	[mmol/L]	1,19	0,03	3,3	305	2	CVP	1,19	0,054	11%	1,05	1,33	305	303	99%							0		
Other					2	0							2											
1x 0, 1x 99																								
<b>(8) Lithium</b>					44							44	41	93%								0		
Samples and groups																								
<b>Sample A</b>	[mmol/L]	1,75	0,08	4,6	44	9	CVP	1,75	0,030	12%	1,54	1,96	44	42	95%							0		
(1) Flame emission phot.		1,78	0,03	2,1	9	0							9											
(3) ISE		1,77	0,09	5,6	15	0							15											
(4) Photometry		1,73	0,07	4,4	17	0							17											
Other					3	0							3											
2x 2, 1x 99																								
<b>Sample B</b>	[mmol/L]	0,997	0,05	5,0	44	9	CVP	0,997	0,019	12%	0,877	1,12	44	41	93%							0		
(1) Flame emission phot.		1,01	0,01	1,5	9	0							9											
(3) ISE		1,01	0,04	4,4	15	0							15											
(4) Photometry		0,979	0,06	6,3	17	0							17											
Other					3	0							3											
2x 2, 1x 99																								
<b>(9) Total protein</b>					341								0								341	337	99%	
Samples and groups																								
<b>Sample A</b>	[g/L]	48,6	1,3	2,7	341	0							0	CRV	48,79	0,58	9%	44,3	53,2	341	338	99%		
(1) Biuret		48,6	1,3	2,7	341	0															341			
<b>Sample B</b>	[g/L]	55,5	1,4	2,5	341	0							0	CRV	55,54	0,66	9%	50,5	60,6	341	339	99%		
(1) Biuret		55,5	1,4	2,5	341	0															341			
<b>(10) Albumin</b>					333								333	329	99%							0		
Samples and groups																								
<b>Sample A</b>	[g/L]	32,1	1,3	4,2	333	0	CVP	32,1	0,18	10%	28,8	35,4	333	330	99%							0		
(1) BCG		32,2	1,3	4,1	307	0							307											
(2) BCP		31,2	1,1	3,5	26	0							26											
<b>Sample B</b>	[g/L]	35,3	1,5	4,1	333	0	CVP	35,3	0,20	10%	31,7	38,9	333	331	99%							0		
(1) BCG		35,4	1,4	3,9	307	0							307											
(2) BCP		33,9	1,4	4,1	26	0							26											
<b>(11) Osmolality</b>					127								127	124	98%							0		
Samples and groups																								
<b>Sample A</b>	[mmol/kg]	279	4,3	1,5	127	2	CVP	279	0,94	5%	265	293	127	126	99%							0		
(1) Osmometer		280	4,2	1,5	125	0							125											
Other					2	0							2											
2x 99																								
<b>Sample B</b>	[mmol/kg]	254	4,5	1,8	127	2	CVP	254	0,99	5%	241	267	127	125	98%							0		
(1) Osmometer		255	4,5	1,8	125	0							125											
Other					2	0							2											
2x 99																								
<b>(12) Lactate</b>					154								154	148	96%							0		
Samples and groups																								
<b>Sample A</b>	[mmol/L]	3,37	0,14	4,3	154	2	CVP	3,37	0,029	15%	2,86	3,88	154	152	99%							0		

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability						Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(12) Lactate</b>					154							154	148	96%							0			
Samples and groups	[mmol/L]																							
<b>Sample A</b>		3,37	0,14	4,3	154		CVP	3,37	0,029	15%	2,86	3,88		154	152	99%						0		
(1) UV enzyme method		3,36	0,14	4,2	71	0								71										
(2) Enzyme electrodes		3,47	0,23	6,5	13	0								13										
(3) Photometric enzyme method		3,37	0,13	4,0	70	1								70										
<b>Sample B</b>		5,84	0,26	4,4	154		CVP	5,84	0,051	15%	4,96	6,72		154	149	97%						0		
(1) UV enzyme method		5,82	0,25	4,2	71	1								71										
(2) Enzyme electrodes		5,80	0,45	7,8	13	0								13										
(3) Photometric enzyme method		5,86	0,25	4,3	70	1								70										
<b>(13) Bilirubin total</b>					363									0							363	339	93%	
Samples and groups	[µmol/L]																							
<b>Sample A</b>		55,7	4,6	8,2	363									0		CRV	52,2	1,6	21%	41,2	63,2	363	349	96%
(1) Jendrassik-Gróf		56,1	4,8	8,5	61	0																	61	
(2) DCA, DPD		55,2	4,5	8,1	272	0																	272	
(4) Oxidation-reduction methods		59,4	2,3	3,9	28	0																	28	
Other					2	0																	2	
<b>Sample B</b>		23,3	2,5	11	363									0		2x 99 CRV	22	0,70	21%	17,3	26,7	363	346	95%
(1) Jendrassik-Gróf		23,7	2,6	11	61	0																	61	
(2) DCA, DPD		23,0	2,6	11	272	0																	272	
(4) Oxidation-reduction methods		24,7	1,0	4,1	28	0																	28	
Other					2	0																	2	
<b>(15) Cholesterol</b>					349									10	7	70%						339	314	93%
Samples and groups	[mmol/L]																							
<b>Sample A</b>		2,77	0,11	4,0	349									10	7	70%						339	316	93%
(1) Enzyme method CHOD-PAP		2,77	0,11	3,8	338	0										CRV	2,874	0,029	9%	2,61	3,14	338		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade)		2,25	0,15	6,9	10	0	CVPG	2,25	0,12	6,5%	2,1	2,4		10									1	
Other					1	0																	1	
<b>Sample B</b>		3,15	0,12	3,8	349									10	9	90%						339	337	99%
(1) Enzyme method CHOD-PAP		3,15	0,12	3,7	338	0										CRV	3,179	0,032	9%	2,89	3,47	338		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade)		2,88	0,14	5,0	10	0	CVPG	2,88	0,11	6,5%	2,69	3,07		10									1	
Other					1	0																	1	
<b>(16) Glucose</b>					365									0								365	352	96%
Samples and groups	[mmol/L]																							
<b>Sample A</b>		5,32	0,14	2,7	365									0		CRV	5,228	0,052	8%	4,8	5,65	365	354	97%
(1) GOD photometry		5,34	0,19	3,6	92	0																	92	
(2) GOD electrochemical		5,34	0,05	1,1	6	0																	6	
(3) Method with hexokinase		5,31	0,13	2,5	267	0																	267	
<b>Sample B</b>		13,6	0,34	2,5	365									0		CRV	13,36	0,13	8%	12,2	14,5	365	359	98%
(1) GOD photometry		13,6	0,37	2,8	92	0																	92	
(2) GOD electrochemical		13,5	0,22	1,7	6	0																	6	
(3) Method with hexokinase		13,6	0,34	2,5	267	0																	267	

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability															
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>								
<b>(17) Uric acid</b>					357							0				357	353	99%				
Samples and groups	[µmol/L]																					
<b>Sample A</b>		237	10	4,4	357							0	CRV	234,3	2,3	12%	206	263	357	354	99%	
(2) Enzyme-photomet. m.		237	10	4,4	357	0													357			
<b>Sample B</b>		345	12	3,4	357							0	CRV	339,6	3,4	12%	298	381	357	355	99%	
(2) Enzyme-photomet. m.		345	12	3,4	357	0													357			
<b>(18) Urea</b>					364							0							364	362	99%	
Samples and groups	[mmol/L]																					
<b>Sample A</b>		9,91	0,39	3,9	364							0	CRV	10,1	0,12	15%	8,58	11,7	364	363	100%	
(1) UV enzymatic m.(GMD)		9,90	0,39	3,9	354	0													354			
(5) Electrochemical m.		10,1	0,22	2,2	7	0													7			
Other					3	0													3			
<b>Sample B</b>		4,91	0,22	4,4	364							0	CRV	4,99	0,050	15%	4,24	5,74	364	363	100%	
(1) UV enzymatic m.(GMD)		4,91	0,22	4,4	354	0													354			
(5) Electrochemical m.		5,15	0,22	4,3	7	0													7			
Other					3	0													3			
														2x 2, 1x 99								
<b>(19) Creatinine</b>					366							0							366	357	98%	
Samples and groups	[µmol/L]																					
<b>Sample A</b>		488	17	3,5	366							0	CRV	484,6	4,8	13%	421	548	366	365	100%	
(1) Jaffe		480	18	3,8	182	0													182			
(3) Enzyme		495	13	2,6	184	0													184			
<b>Sample B</b>		118	4,6	3,9	366							0	CRV	115,6	1,2	13%	100	131	366	358	98%	
(1) Jaffe		119	5,2	4,4	182	0													182			
(3) Enzyme		117	4,2	3,6	184	0													184			
<b>(20) Triglycerides</b>					346							0							346	342	99%	
Samples and groups	[mmol/L]																					
<b>Sample A</b>		2,47	0,07	3,0	346							0	CRV	2,437	0,028	15%	2,07	2,81	346	345	100%	
(1) Photometric enzyme (GPO-PAP)		2,47	0,07	2,9	331	0													331			
(2) Enzymatic UV method		2,42	0,11	4,5	15	0													15			
<b>Sample B</b>		1,21	0,04	3,9	346							0	CRV	1,186	0,013	15%	1	1,37	346	342	99%	
(1) Photometric enzyme (GPO-PAP)		1,21	0,04	3,8	331	0													331			
(2) Enzymatic UV method		1,19	0,06	5,8	15	0													15			
<b>(21) ALP</b>					358							0							358	352	98%	
Samples and groups	[µkat/L]																					
<b>Sample A</b>		7,26	1,0	14	358							0	CRV	7,316	0,18	28%	5,26	9,37	358	355	99%	
(3) IFCC method		7,25	1,0	14	356	0													356			
Other					2	0													2			
<b>Sample B</b>		9,12	1,4	15	358							0	CRV	9,289	0,22	28%	6,68	11,9	358	352	98%	
(3) IFCC method		9,11	1,4	15	356	0													356			
Other					2	0													2			
														2x 1								

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(22) alpha-amylase</b>					342							10	10	100%						332	325	98%	
Samples and groups	[µkat/L]																						
<b>Sample A</b>		3,46	0,18	5,1	342							10	10	100%						332	327	98%	
(1) IFCC method		3,45	0,17	4,9	332	0									CRV	3,439	0,100	15%	2,92	3,96	332		
(1) IFCC method; (149) Siemens (Dade)		4,22	0,03	0,88	9	0	CVPG	4,23	0,11	9,5%	3,82	4,64											
Other					1	0																	
							1x 0/149																
<b>Sample B</b>		4,19	0,22	5,2	342							10	10	100%						332	325	98%	
(1) IFCC method		4,18	0,21	4,9	332	0									CRV	4,193	0,12	15%	3,56	4,83	332		
(1) IFCC method; (149) Siemens (Dade)		5,19	0,05	1,0	9	0	CVPG	5,21	0,12	9,5%	4,71	5,71											
Other					1	0																	
							1x 0/149																
<b>(23) AST</b>					363															363	354	98%	
Samples and groups	[µkat/L]																						
<b>Sample A</b>		4,08	0,17	4,2	363										CRV	4,081	0,093	15%	3,46	4,7	363	355	98%
(1) IFCC method		4,08	0,17	4,2	362	0																	
Other					1	0																	
<b>Sample B</b>		1,50	0,07	4,9	363										1x 99 CRV	1,482	0,035	15%	1,25	1,71	363	360	99%
(1) IFCC method		1,50	0,07	4,9	362	0																	
Other					1	0																	
<b>(24) ALT</b>					363															363	351	97%	
Samples and groups	[µkat/L]																						
<b>Sample A</b>		3,49	0,13	3,7	363										CRV	3,487	0,080	15%	2,96	4,02	363	359	99%
(1) IFCC method		3,49	0,13	3,7	362	0																	
Other					1	0																	
<b>Sample B</b>		1,59	0,07	4,6	363										1x 99 CRV	1,565	0,037	15%	1,33	1,8	363	354	98%
(1) IFCC method		1,59	0,07	4,6	362	0																	
Other					1	0																	
<b>(26) CK</b>					323															323	312	97%	
Samples and groups	[µkat/L]																						
<b>Sample A</b>		8,94	0,68	7,6	323										CRV	9,264	0,26	20%	7,41	11,2	323	314	97%
(1) IFCC method		8,94	0,68	7,6	323	0																	
<b>Sample B</b>		3,29	0,18	5,4	323										CRV	3,312	0,12	20%	2,64	3,98	323	317	98%
(1) IFCC method		3,29	0,18	5,4	323	0																	
<b>(27) gamma-GT</b>					358															358	351	98%	
Samples and groups	[µkat/L]																						
<b>Sample A</b>		3,62	0,13	3,7	358										CRV	3,702	0,098	15%	3,14	4,26	358	355	99%
(1) IFCC method		3,62	0,13	3,7	358	0																	
<b>Sample B</b>		1,65	0,06	3,7	358										CRV	1,724	0,043	15%	1,46	1,99	358	352	98%
(1) IFCC method		1,65	0,06	3,7	358	0																	

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(28) LD</b>					258							0									258	256	99%	
Samples and groups	[µkat/L]																							
<b>Sample A</b>		3,79	0,15	4,0	258							0		CRV	3,806	0,087	18%	3,12	4,5	258	256	99%		
(3) IFCC method		3,79	0,15	4,0	258	0															258			
<b>Sample B</b>		6,51	0,20	3,1	258							0		CRV	6,463	0,14	18%	5,29	7,63	258	257	100%		
(3) IFCC method		6,51	0,20	3,1	258	0															258			
<b>(29) Lipase</b>					159							147	140	95%									0	
Samples and groups	[µkat/L]																							
<b>Sample A</b>		4,35	0,80	18	159							147	142	97%									0	
(0) Not specified; (1) Abbott		4,64	0,27	5,8	22	0	CVPG	4,64	0,14	24%	3,52	5,76											22	
(0) Not specified; (12) Beckman Coulter		4,61	0,22	4,8	9	0	CVPG	4,61	0,27	24%	3,5	5,72											9	
(0) Not specified; (46) Erba Lachema		2,96	0,50	17	5	0	CVPG	2,96	1,4	24%	2,24	3,68											5	
(0) Not specified; (58) Beckman Coulter (Olympus)		4,78	0,21	4,5	39	0	CVPG	4,78	0,084	24%	3,63	5,93											39	
(0) Not specified; (60) Roche		3,71	0,64	17	56	0	CVPG	3,71	0,21	24%	2,81	4,61											56	
(0) Not specified; (179) Siemens (Bayer)		5,38	0,52	9,7	16	0	CVPG	5,38	0,32	24%	4,08	6,68											16	
Other					12	0																	0	
								2x 0/49, 2x 0/149, 3x 0/177, 3x 0/178, 2x 0/999																0
<b>Sample B</b>		0,498	0,03	7,8	159							147	145	99%									0	
(0) Not specified; (1) Abbott		0,518	0,03	6,7	22	0	CVPG	0,518	0,018	24%	0,393	0,643											22	
(0) Not specified; (12) Beckman Coulter		0,490	0,03	6,1	9	0	CVPG	0,49	0,037	24%	0,372	0,608											9	
(0) Not specified; (46) Erba Lachema		0,565	0,02	3,9	5	0	CVPG	0,565	0,063	24%	0,429	0,701											5	
(0) Not specified; (58) Beckman Coulter (Olympus)		0,475	0,02	5,9	39	0	CVPG	0,475	0,011	24%	0,361	0,589											39	
(0) Not specified; (60) Roche		0,484	0,01	3,9	56	0	CVPG	0,484	0,063	24%	0,367	0,601											56	
(0) Not specified; (179) Siemens (Bayer)		0,609	0,05	9,1	16	0	CVPG	0,609	0,034	24%	0,462	0,756											16	
Other					12	0																	0	
								2x 0/49, 2x 0/149, 3x 0/177, 3x 0/178, 2x 0/999																0
<b>(30) Cholinesterase</b>					114							111	106	95%									0	
Samples and groups	[µkat/L]																							
<b>Sample A</b>		100	4,8	4,8	114							111	106	95%									0	
(1) Standard method		100	4,6	4,6	111	0	CVP	100	1,1	12%	88	112											111	
Other					3	0																	0	
								3x 1/149																
<b>Sample B</b>		94,4	4,2	4,4	114							111	106	95%									0	
(1) Standard method		94,2	3,9	4,2	111	0	CVP	94,2	0,92	12%	82,8	106											111	
Other					3	0																	0	
								3x 1/149																
<b>(31) Albumin (elpho)</b>					94							94	93	99%									0	
Samples and groups	[-]																							
<b>Sample A</b>		0,648	0,03	5,2	94		CVP	0,648	0,085	15%	0,55	0,746											0	
(0) Not specified		0,648	0,03	5,2	94	0																	94	
<b>Sample B</b>		0,626	0,03	5,0	94		CVP	0,626	0,080	15%	0,532	0,72											0	
(0) Not specified		0,626	0,03	5,0	94	0																	94	

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS2/19 - Basic Clinical Chemistry - Serum

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(32) gamma-globuline (elpho)</b>					94							94	92	98%									0
Samples and groups	[-]																						
<b>Sample A</b>		0,122	0,01	11	94	CVP	0,122	0,035	30%	0,085	0,159	94	92	98%									0
(0) Not specified		0,122	0,01	11	94							94											
<b>Sample B</b>		0,136	0,01	9,7	94	CVP	0,136	0,033	30%	0,095	0,177	94	94	100%									0
(0) Not specified		0,136	0,01	9,7	94							94											
<b>(35) alpha-amylase pancreatic</b>					95							95	91	96%									0
Samples and groups	[µkat/L]																						
<b>Sample A</b>		2,88	0,11	3,9	95	CVP	2,88	0,028	10%	2,59	3,17	95	93	98%									0
(1) With IFCC calibration		2,88	0,11	3,9	95							95											
<b>Sample B</b>		3,61	0,14	3,8	95	CVP	3,61	0,034	10%	3,24	3,98	95	92	97%									0
(1) With IFCC calibration		3,61	0,14	3,8	95							95											
<b>(36) Calcium ionised</b>					55							55	53	96%									0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		1,62	0,06	3,9	55	CVP	1,62	0,021	10%	1,45	1,79	55	53	96%									0
(2) Direct ISE		1,62	0,06	3,8	51							51											
Other					4							4											
						1x 0, 3x 1																	
<b>Sample B</b>		1,14	0,03	3,0	55	CVP	1,14	0,011	10%	1,02	1,26	55	53	96%									0
(2) Direct ISE		1,14	0,03	2,8	51							51											
Other					4							4											
						1x 0, 3x 1																	

st\_kn\_np

End of report

Printed: 19.04.2019